Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | CDA | P32320 | 7/20 | 0.35 |
| ▸ | TREH | O43280 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PYGB | P11216 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24256353 | 1.00 | LMNA (0.37) | LMNAGBA1LGALS3CDATREH | |
| SCHEMBL24256516 | 0.82 | TREH (0.36) | LMNAGBA1LGALS3CDATREH | |
| SCHEMBL23705442 | 0.82 | TREH (0.36) | LMNAGBA1LGALS3CDATREH | |
| SCHEMBL26879310 | 0.81 | LMNA (0.33) | LMNAGBA1LGALS3CDATREH | |
| SCHEMBL24256834 | 0.81 | LMNA (0.33) | LMNAGBA1LGALS3CDATREH | |
| SCHEMBL26900891 | 0.81 | CDA (0.43) | LMNAGBA1LGALS3CDATREH | |
| SCHEMBL23705229 | 0.81 | CDA (0.43) | LMNAGBA1LGALS3CDATREH | |
| SCHEMBL24256355 | 0.80 | LGALS3 (0.33) | LMNAGBA1LGALS3CDATREH | |
| SCHEMBL23705298 | 0.80 | LGALS3 (0.33) | LMNAGBA1LGALS3CDATREH | |
| SCHEMBL23705157 | 0.78 | CDA (0.42) | LMNAGBA1LGALS3CDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| EP-4097138-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | Avila Therapeutics, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115066438-A | ASGPR binding compounds for degrading extracellular proteins | 阿维拉治疗公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021155317-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | LMNA 2955/4885GBA1 150/4885LGALS3 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.